PRINCETON, N.J., Oct. 6, 2005 (PRIMEZONE) -- The Bull Market Report (http://www.bullmarket.com), a long-term growth and income-generating focused online investment newsletter, announced today that it has provided subscribers with a detailed look at Pfizer (NYSE:PFE) and the challenges and opportunities the company faces, in particular regarding its $10 billion a year blockbuster, Lipitor.
All paid and trial subscribers to The Bull Market Report can now receive immediate access to The Bull Market Report's exclusive daily reports. As a trial or paid subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today:
https://www.bullmarket.com/subscribe/?refer=BMR46
In discussing Pfizer, The Bull Market Report wrote: "While Lipitor will continue to anchor Pfizer's results, the challenges that this blockbuster drug is facing once more highlight the evolution of the drug industry and Pfizer's response to those changes. Between tougher regulatory scrutiny and generic competition, the industry is struggling to produce growth and it has therefore put more emphasis on reducing costs. Pfizer has definitely picked up the 'streamlining' mantra this year. At the same time, however, the company is intensely focused on its pipeline and on opportunities to partner with and/or buy biotechnology companies."
In its recent stock market coverage, The Bull Market Report looked at the following topics, among many others:
-- How will Express Scripts' (Nasdaq:ESRX) recommendation to its customers to remove Lipitor from their preferred drug lists next year affect Pfizer?
-- Will rival prescription anti-cholesterol drugs, such as Crestor from Astrazeneca (NYSE:AZN) or Vytorin from Schering-Plough (NYSE:SGP), cut into Lipitor sales?
-- What positives does Pfizer (and Lipitor) have going for it?
-- Does Pfizer's stock represent a good buying opportunity?
About The Bull Market Report:
Launched in 1997, The Bull Market Report has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The Bull Market Report's Recommended List includes over 50 companies across all major industries, including financials, health care, energy, technology, and retail, among others. As a testament to the durability of its value-focused and fundamentally sound recommendations in both up and down markets, The Bull Market Report is one of the oldest continuously published investment newsletters online. Start your 14-day free trial today:
https://www.bullmarket.com/subscribe/?refer=BMR46
Subscribers also receive access to The Bull Market Report's special bonus reports, "Search Sector Outlook," "Biotech Sector Outlook," and "Understanding the Value of Insider Trading Data."
Note: This release was published by F.P. Real Ventures I, LLC (CRD #131926). Indie Research, LLC and the Bull Market editorial staff are not registered investment advisors, broker/dealers, or research analysts/organizations.